Baseline characteristics (N = 27)
| . | Median (range) or n (%) . |
|---|---|
| Median age (y) | 70 (56-86) |
| Male:female | 16 (59%):11 (41%) |
| NYHA class | |
| 1 | 12 (44%) |
| 2 | 14 (52%) |
| 3 | 1 (4%) |
| 4 | 0 |
| ECOG | |
| 0 | 7 (26%) |
| 1 | 15 (56%) |
| 2 | 5 (18%) |
| 3 | 0 |
| 4 | 0 |
| Cardiac involvement | 17 (63%) |
| Median NT-pro-BNP (ng/L) | 978 (42-5708) |
| Median cardiac troponin T (ng/L) | 31.5 (3-122) |
| Mayo stage | |
| I | 8 (30%) |
| II | 13 (48%) |
| IIIA (NT-pro-BNP ≤8500 ng/L) | 6 (22%) |
| IIIB (NT-pro-BNP >8500 ng/L) | 0 |
| Median systolic blood pressure (mmHg) | 119 (100-164) |
| Median left ventricular wall thickness (mm) | 11 (8.5-18) |
| Median LV ejection fraction (%) | 60 (36-72) |
| Renal involvement | 17 (63%) |
| Median serum creatinine (μmol/L) | 98 (46-493) |
| Median GFR (mL/min) | 68 (10-100) |
| Median proteinuria (g/24 h) | 0.8 (0.1-34.6) |
| Liver involvement | 6 (22%) |
| Median serum bilirubin (μmol/L) | 6 (2-50) |
| Median ALP (U/L) | 105 (25-1879) |
| Soft tissue involvement | 2 (7%) |
| Peripheral nerve involvement | 6 (22%) |
| Autonomic nerve involvement | 4 (15%) |
| Lymph node involvement | 13 (48%) |
| GI involvement | 0 |
| Median number of involved organs | 1 (1-4) |
| Involved light chains | |
| κ | 7 (26%) |
| Λ | 12 (44%) |
| No monoclonal light-chain excess | 8 (30%) |
| Median dFLC (mg/L) | 59.8 (2.2-856.4) |
| IgM κ M-protein, IgM λ M-protein | 11 (44%), 14 (56%) |
| Median serum monoclonal protein (g/L) | 11.5 (1-30) |
| . | Median (range) or n (%) . |
|---|---|
| Median age (y) | 70 (56-86) |
| Male:female | 16 (59%):11 (41%) |
| NYHA class | |
| 1 | 12 (44%) |
| 2 | 14 (52%) |
| 3 | 1 (4%) |
| 4 | 0 |
| ECOG | |
| 0 | 7 (26%) |
| 1 | 15 (56%) |
| 2 | 5 (18%) |
| 3 | 0 |
| 4 | 0 |
| Cardiac involvement | 17 (63%) |
| Median NT-pro-BNP (ng/L) | 978 (42-5708) |
| Median cardiac troponin T (ng/L) | 31.5 (3-122) |
| Mayo stage | |
| I | 8 (30%) |
| II | 13 (48%) |
| IIIA (NT-pro-BNP ≤8500 ng/L) | 6 (22%) |
| IIIB (NT-pro-BNP >8500 ng/L) | 0 |
| Median systolic blood pressure (mmHg) | 119 (100-164) |
| Median left ventricular wall thickness (mm) | 11 (8.5-18) |
| Median LV ejection fraction (%) | 60 (36-72) |
| Renal involvement | 17 (63%) |
| Median serum creatinine (μmol/L) | 98 (46-493) |
| Median GFR (mL/min) | 68 (10-100) |
| Median proteinuria (g/24 h) | 0.8 (0.1-34.6) |
| Liver involvement | 6 (22%) |
| Median serum bilirubin (μmol/L) | 6 (2-50) |
| Median ALP (U/L) | 105 (25-1879) |
| Soft tissue involvement | 2 (7%) |
| Peripheral nerve involvement | 6 (22%) |
| Autonomic nerve involvement | 4 (15%) |
| Lymph node involvement | 13 (48%) |
| GI involvement | 0 |
| Median number of involved organs | 1 (1-4) |
| Involved light chains | |
| κ | 7 (26%) |
| Λ | 12 (44%) |
| No monoclonal light-chain excess | 8 (30%) |
| Median dFLC (mg/L) | 59.8 (2.2-856.4) |
| IgM κ M-protein, IgM λ M-protein | 11 (44%), 14 (56%) |
| Median serum monoclonal protein (g/L) | 11.5 (1-30) |
ALP, alkaline phosphatase; dFLC, difference between involved and uninvolved light chains; ECOG, Eastern Cooperative Oncology Group; GFR, glomerular filtration rate; GI, gastrointestinal; LV, left ventricular; NT-pro-BNP, N-terminal pro–brain natriuretic peptide; NYHA, New York Heart Association.